# Iparomlimab and Tuvonralimab Combined With Platinum-Based Chemotherapy for Neoadjuvant Treatment of Cervical Cancer

> **NCT06986057** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shandong Tumor Hospital** · enrollment: 28 (estimated)

## Conditions studied

- Cervical Cancer
- Neoadjuvant Therapy

## Interventions

- **DRUG:** Iparomlimab and tuvonralimab (QL1706) combined with platinum-based chemotherapy

## Key facts

- **NCT ID:** NCT06986057
- **Lead sponsor:** Shandong Tumor Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-31
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2025-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06986057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06986057, "Iparomlimab and Tuvonralimab Combined With Platinum-Based Chemotherapy for Neoadjuvant Treatment of Cervical Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06986057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*